Aerovate Therapeutics Inc (AVTE) — Tangible Net Worth Ratio
Aerovate Therapeutics Inc (AVTE) has a Tangible Net Worth Ratio of 100.0% as of March 2025. This metric is calculated by deducting intangible assets ($0.00) from net assets ($75.05 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See AVTE working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Aerovate Therapeutics Inc Tangible Net Worth Ratio (2021–2024)
This chart shows how Aerovate Therapeutics Inc's Tangible Net Worth Ratio has changed across 4 annual periods from 2021 to 2024. As of March 2025, the ratio stands at 100.0%, reflecting net assets of $75.05 Million with intangible assets of $0.00 USD. See Aerovate Therapeutics Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Aerovate Therapeutics Inc (2021–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for Aerovate Therapeutics Inc from 2021 to 2024, covering 4 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see Aerovate Therapeutics Inc market cap and net worth.
| Year | Tangible NW Ratio | Net Assets (USD) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 100.0% | $76.43 Million | $0.00 | $80.33 Million | ▲ +0.0 pp |
| 2023 | 100.0% | $109.46 Million | $0.00 | $127.42 Million | ▲ +0.0 pp |
| 2022 | 100.0% | $126.74 Million | $0.00 | $135.30 Million | ▲ +0.0 pp |
| 2021 | 100.0% | $172.42 Million | $0.00 | $175.36 Million | — |